



US 20210393779A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0393779 A1**
(43) **Pub. Date: Dec. 23, 2021**
Kamen et al.(54) **ACTIVIN A ANTIBODY FORMULATIONS
AND METHODS OF USE THEREOF***A61K 47/26* (2006.01)*A61K 47/18* (2006.01)(71) Applicant: **Regeneron Pharmaceuticals, Inc.**,
Tarrytown, NY (US)(52) **U.S. Cl.**CPC *A61K 39/39591* (2013.01); *C07K 16/22*
(2013.01); *A61K 47/183* (2013.01); *A61K*
47/26 (2013.01); *A61K 47/22* (2013.01)(72) Inventors: **Douglas Kamen**, Poughquag, NY (US);
Kenneth Graham, Pleasant Valley, NY
(US)(21) Appl. No.: **17/351,354**

(57)

ABSTRACT(22) Filed: **Jun. 18, 2021****Related U.S. Application Data**(60) Provisional application No. 63/040,589, filed on Jun.
18, 2020.**Publication Classification**(51) **Int. Cl.***A61K 39/395* (2006.01)*C07K 16/22* (2006.01)*A61K 47/22* (2006.01)

The present invention provides novel pharmaceutical formulations comprising an antibody that specifically binds to human Activin A. The formulations may contain, in addition to an anti-Activin A antibody, a histidine buffer, an organic cosolvent, and a thermal stabilizer. The pharmaceutical formulations of the present invention exhibit a surprising degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.

Specification includes a Sequence Listing.